Decreased has-miR-1246 expression in B cells from systemic lupus erythematosus (SLE). (A) High-throughput miRNA microarray of the activities of 371 miRNAs isolated from B cells of healthy controls (n = 11) and active SLE patients (n = 11). Imbalance of green and red signal signifies non-equivalent activities. (B) Scatter plot of the results in (A); down-expressed miRNAs in active SLE patient samples are indicated by the green oval. (C) Fold-change of the six miRNAs was found to differ between SLE and control samples. (D, E) Expression of miR-1246 as measured by miRNA real-time reverse transcription-polymerase chain reaction (RT-PCR) in B cells from 30 active SLE patients (19 were being treated with corticosteroids, antimalarials, or immunosuppressive agents and 11 were untreated), 20 inactive SLE patients, and 20 age- and sex-matched healthy control subjects. Transcript levels were significantly reduced in patients with active SLE, regardless of whether they were receiving concurrent medications, while no significant difference between healthy controls and inactive SLE patients. Bars in (D, E) show the mean ± SD results in 20 healthy donors, 30 patients with active SLE, and 20 patients with inactive SLE. All experiments were performed in triplicate. (**P < 0.01).